The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
Official Title: A Phase 1b/2 Multiple-Dose Study to Evaluate the Safety and Efficacy of XmAb18087 ± Pembrolizumab in Subjects With Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer (DUET-1-02) Protocol
Study ID: NCT04590781
Brief Summary: This is a Phase 1b/2, multiple-dose study designed to describe safety and efficacy, and to assess PK and immunogenicity of XmAb18087 monotherapy and in combination with pembrolizumab in participants with metastatic Merkel cell (MCC) or locoregional MCC that has recurred after locoregional therapy with surgery and/or radiation therapy, and mAb18087 monotherapy in participants with extensive-stage small cell lung cancer (SCLC) that has progressed after standard therapies. This study was terminated by the sponsor. No participants enrolled in Part B.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
City of Hope, Duarte, California, United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Memorial Sloan Kettering, New York, New York, United States
OU Health, Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Swedish Cancer Institute, Seattle, Washington, United States
University of Washington, Seattle, Washington, United States
Name: Benjamin Thompson, MD, PhD
Affiliation: Medical Director, Clinical Development, Xencor
Role: STUDY_DIRECTOR